5 Key Takeaways

• 1

  Manufacturability is the primary challenge for scaling cell and gene therapies.

• 2

  Cost, funding pressures, and specialized expertise significantly impact the success of innovations in advanced medicines.

• 3

  Emerging solutions like digital twins and advances in AAV quality control are enhancing therapy production.

• 4

  Workforce development, automation, and decentralization are crucial for making advanced therapies more accessible.

• 5

  Robotics, AI, and next-generation manufacturing platforms are expected to reduce costs and improve treatment consistency.